Nontuberculous Mycobacterial Infection Market Report 2024 - NTM Infection Market Trends And Forecast To 2034

 What is the current market size and future outlook for the nontuberculous mycobacterial infection market?

The nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $14.25 billion in 2024 to $15.11 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to improved diagnostics, aging population, cystic fibrosis awareness, immunosuppressive medications.

The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to $19.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to antimicrobial drug development, increasing ntm awareness, advances in genetic research, telehealth and remote monitoring. Major trends in the forecast period include personalized treatment, regulatory focus, combination therapies, digital health tools.



Get Your Free Sample of The Global Nontuberculous Mycobacterial Infection Market Report:
Nontuberculous Mycobacterial Infection Market Report 2025

What are the key drivers behind the rapid expansion of the nontuberculous mycobacterial infection market?

The rising prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel the growth of the nontuberculous mycobacterial infection market going forward. Chronic obstructive pulmonary disease (COPD) is a chronic respiratory condition characterized by persistent and often progressive lung airflow limitation. Nontuberculous mycobacterial (NTM) infections in patients with COPD are associated with a more significant decline in forced expiratory volume in one second (FEV1) and an increased exacerbation rate. COPD may weaken the immune system and damage the lung tissue, making it easier for NTM bacteria to infect the lungs. For instance, in March 2023, according to a report published by The Scottish Public Health Observatory (ScotPHO), a Scotland-based public health body, COPD rates began to climb between 2021 and 2022, with male rates increasing from 83.2 to 97.6 per 100,000 persons while female rates increased from 72.6 to 97.3. Therefore, the rising prevalence of chronic obstructive pulmonary disease (COPD) drives the growth of the nontuberculous mycobacterial infection market.

What is the segmentation for the nontuberculous mycobacterial infection market?
The nontuberculous mycobacterial infection market covered in this report is segmented –

1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Macrolides: Azithromycin, Clarithromycin
2) By Rifampin: Rifampin, Rifabutin
3) By Aminoglycoside: Amikacin, Streptomycin
4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid

Order your report now for swift delivery
Nontuberculous Mycobacterial Infection Market Report 2025

Who are the most influential companies in the nontuberculous mycobacterial infection market?

Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

What are the most influential trends expected to drive the nontuberculous mycobacterial infection market forward?

Major companies operating in the nontuberculous mycobacterial infection market adopt new treatment approval practices such as fast track designation for drug approval to sustain their position in the market. Fast Track designation by the FDA is a process designed to expedite the development and review of drugs for serious conditions with unmet medical needs. For instance, in July 2022, the Food and Drug Administration, a U.S.-based federal agency, granted Fast Track Designation for NUZYRA to treat nontuberculous mycobacterial (NTM) lung disease due to Mycobacterium avium complex (MAC). NUZYRA (omadacycline) is a novel broad-spectrum antibiotic designed to combat serious bacterial infections, including those caused by resistant strains. This designation facilitates expedited development and review processes for NUZYRA antibiotic for addressing significant unmet medical needs.

What are the major regional insights for the nontuberculous mycobacterial infection market, and which region holds the top position?

North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Does The Nontuberculous Mycobacterial Infection Market Report 2025 Offer?

The nontuberculous mycobacterial infection market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.

A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than mycobacterium tuberculosis, which is responsible for tuberculosis (TB). The role of nontuberculous mycobacterial (NTM) infections is primarily related to their impact on human health and their interaction with the immune system.

Purchase the exclusive report now to unlock valuable market insights:
Nontuberculous Mycobacterial Infection Market Report 2025

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Twitter: The Business Research Company (@tbrc_info) on X
Facebook: The Business Research Company | London
YouTube: The Business Research Company
Blog: Future Outlook of the Electrical And Electronics Ceramics Market: Growth, Trends, and Emerging Opportunities Explored - Latest Global Market Insights
Healthcare Blog: Latest Healthcare Research Reports - By The Business Research Company
Global Market Model: Global Market Intelligence Database